A calculation can be internally consistent while the underlying treatment plan remains unsupported. That is the central problem with online requests to confirm KPV amounts: arithmetic addresses quantities, not whether the product, exposure or intended use is appropriate.
Identify the unanswered questions first
FDA's 2026 KPV evaluation described major gaps in human exposure and clinical evidence. A calculation cannot fill those gaps. It cannot establish the amount that improves a condition, the exposure that produces it or the risks associated with a specific formulation.
Nor does a correct calculation verify that the label accurately describes the material. Those are independent questions requiring different kinds of evidence.
Measurement units are not a treatment standard
Mass, concentration and device markings describe different quantities. Recognizing the distinction is important, but an educational explanation should not become a recipe for self-administration of an investigational compound.
This article deliberately provides no mixing ratios, syringe conversions or worked example. The absence of those details is not a missing answer to a medical question: the medically important question is whether there is a validated regimen to calculate in the first place.
Why copying a study does not solve the problem
An experimental amount belongs to the study's species, formulation, route and outcome. Changing any of those features requires justification. Scaling an animal exposure or borrowing a number from another person's experience does not create that justification.
A study may also explore an amount without establishing it as optimal. To identify a useful regimen, researchers need comparisons, systematic adverse-event collection and a defined population.
The appropriate professional discussion starts with the condition requiring care, the evidence for available options and the actual identity of any proposed product. A pharmacist can clarify measurements for a legitimate prescribed medicine, but mathematical precision should never be presented as proof that an unvalidated KPV protocol is safe. This article is an explanation of the evidence boundary, not an administration guide.